Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
BBC Russian Subscribe
Spotlight

Myelodysplastic Syndromes

Latest News
June 19th 2024

How Inflammation Factors May Influence Lower-Risk MDS

June 13th 2024

Gut Microbiota Found to Influence MDS Risk Through Immune Cells

June 5th 2024

Consortium: PROs Have Key Role in MDS Trials

May 22nd 2024

Key Factors Significantly Associated With ESA Response in Lower-Risk MDS

May 16th 2024

Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS

Video Interviews
View All
March 17th 2024

Dr Jennifer Vaughn: We Can Provide Aggressive, Effective Treatment, but Help Patients Maintain Quality of Life

February 3rd 2023

Treatment Patterns in the Management of MDS

January 27th 2023

Treatment Paradigm in Lower-Risk MDS (LR-MDS) Patients

January 20th 2023

TP53 Mutation and Its Impact on Patient Outcomes in MDS

December 29th 2022

Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS

December 23rd 2022

Dr Patrick Reville: How Patients With MDS, MPAL Responded to Venetoclax With CLIA

December 21st 2022

ASCERTAIN Trial Overview

December 16th 2022

Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIA

November 15th 2022

Key Considerations for Overall MDS Treatment Management

November 15th 2022

Future Treatment of MDS

More News

MDS graphic | Image Credit: MdBabul-stock.adobe.com
May 8th 2024

Diagnostic Oversights Limit Luspatercept Benefits in MDS

Gayle Turim Dickstein
Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept | Image Credit: © ipopba - stock.adobe.com
April 30th 2024

Machine Learning and Neural Network Can Be Effective Diagnostic Tools in MDS, Study Finds

Jared Kaltwasser
The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.
MDS graphic | Image Credit: Sviatlana - stock.adobe.com
April 15th 2024

Improving Cancer Care: The Role of Oral Hypomethylating Agents and Education

Jared Kaltwasser
Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia.
Myelodysplastic syndrome written on a clipboard | Image Credit: syahrir - stock.adobe.com
April 11th 2024

TP53-Mutated MDS/AML Posttransplant Treatment Gaps

Luke Halpern
The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant vs those who did not.
Laptop with words Myelodysplastic Syndrome | Image Credit:Yurii Kibalnik - stock.adobe.com
April 4th 2024

Heterogeneous Practices Common in Treatment, Monitoring of Patients With Myelodysplastic Syndrome With Del(5q)

Luke Halpern
This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones.
Concept of Meylodysplastic Syndrome | Image Credit: syahrir - stock.adobe.com
March 26th 2024

Venetoclax Resistance in Patients With MDS Explained in New Study

Jared Kaltwasser
The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.
MDS Myelodysplastic syndrome | Image Credit: © Sviatlana - stock.adobe.com.jpeg
March 16th 2024

Luspatercept Benefits Transfusion-Dependent Patients With MDS and Anemia in Real-World Study

Jared Kaltwasser
The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.
Bone marrow from MDS | Image credit: tonaquatic - stock.adobe.com
March 9th 2024

Venetoclax/Azacitidine Shows Promise for Relapse Prevention in High-Risk MDS and AML

Luke Halpern
Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Myelodysplastic disease diagnosis | Image credit: ibreakstock - stock.adobe.com
February 28th 2024

Gene Mutations Linked to Adverse Outcomes in AML/MDS

Gwen Mergian
A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell transplant improved survival in this population.
Blood sample for MDS test | Image Credit: MdBabul - stock.adobe.com
February 22nd 2024

Study Describes Characteristics, Outcomes of Patients With Low-Risk MDS

Jared Kaltwasser
Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).
Letter blocks of MDS | Image credit: Sviatlana-stock.adobe.com
February 22nd 2024

Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML

Laura Joszt, MA
Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Businessman presenting concept about research innovation and experiments | Image credit: NicoElNino - stock.adobe.com
February 6th 2024

Signaling Pathways in MDS a Fruitful Area for Research, Drug Development

Jared Kaltwasser
A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.
Psychology and mental health, a female patient feeling nervous in a clinic for support | Image credit: KApeopleimages - stock.adobe.com
February 2nd 2024

Uncertainty, Coping Strategies Common Among Patients With AML, High-Risk MDS

Luke Halpern
Patients with comorbid acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) expressed a desire to discuss treatment options and maintain normalcy; they were not willing to have conversations involving their prognosis and future.
Leukemia cells - LASZLO - stock.adobe.com.jpg
January 26th 2024

Oral and IV Decitabine/Cedazuridine Prove Comparable in MDS

Sabrina Serani
The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.
MDS from stone blocks | Image credit: Sviatlana-stock.adobe.com.
January 26th 2024

Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS

AJMC Staff
Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).
Meylodysplastic syndrome | Image Credit: syahrir - stock.adobe.com
January 23rd 2024

Study Highlights Need for Additional Caregiver Support in Higher-Risk MDS

AJMC Staff
The study, which pulled self-reported data from online bulletin boards across the US, Canada, and the United Kingdom in 2020, found that the degree of burden varied based on patient disease stage, among other factors.
Myelodysplastic syndrome | Image Credit: Sviatlana - stock.adobe.com
January 17th 2024

Online Workshop Reveals Patient, Future Research Priorities in MDS

Maggie L. Shaw
Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, quality of life, and communication with the care team.
Top 5 myelodysplastic syndromes articles of 2023
December 22nd 2023

Top 5 Most-Read Myelodysplastic Syndromes Articles of 2023

Mary Caffrey
An August approval of luspatercept, sold as Reblozyl, which promises to alleviate transfusion burdens for patients with lower-risk MDS, was among the news items that drew readers’ attention.
MDS | Image credit: Astex Pharmaceuticals
December 20th 2023

Data Show Trend Toward Improved Persistence After 6 Months With Oral MDS Regimen

Mary Caffrey
The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).
Reblozyl | image credit: Bristol Myers Squibb
December 16th 2023

COMMANDS: Updated Data for Luspatercept for Treatment of Anemia in ESA-Naïve Patients With Lower-Risk MDS Presented at ASH

Mary Caffrey
The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California.
Zeidan | Image credit: Yale Medical School
December 5th 2023

Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent

Mary Caffrey
The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Women with MDS benefited from a 7-day dosing schedule | Image credit: Moffitt Cancer Center
November 30th 2023

7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males

Mary Caffrey
Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Red Blood Cells | Image credit: Design Cells - stock.adobe.com
November 27th 2023

Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS

Kyle Doherty
Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
November 23rd 2023

ESAs Do Not Improve Hb Levels in Lower-Risk Myelodysplastic Syndrome

Russ Conroy
Data from a retrospective study spotlight a need for more effective first-line and second-line clinical management strategies to improve outcomes in patients with lower-risk myelodysplastic syndrome.
MDS with ring sideroblasts | Girish Venkataraman, MD, MBBS; ASH Image Bank
November 9th 2023

Authors Support Trials of Triplet Therapy in Higher-Risk MDS

Mary Caffrey
Given the likelihood of MDS to progress to acute myeloid leukemia (AML), the authors state, “There are certain settings where ‘AML-like’ therapies are appropriate in MDS, particularly given our evolving understanding of the overlapping biology of these malignancies.”
FDA Approved | Image credit: chrisdorney - stock.adobe.com
October 27th 2023

FDA Approves Ivosidenib in IDH1-Mutated MDS

Ariana Pelosci
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.
Image Credit: Kurhan / Shutterstock
October 20th 2023

Higher Leptin Levels, Body Fat Linked to MDS in Study

Mary Caffrey
The authors discussed a polymorphism of the LEP gene associated not only with cancer, but also with chronic diseases including obesity and diabetes, offering them a reason to look into the relationship between LEP and myelodysplastic syndrome (MDS).
Image Credit: Armed Forces Institute of Pathology
October 15th 2023

Comorbidity Index Predicts Vulnerability of Patients With Myelofibrosis

Mary Caffrey
Investigators evaluated 70 patients in a retrospective study.
blood flowing
October 6th 2023

67% With MDS, AML From Fanconi Anemia Alive at 5 Years Following Allo-HSCT

Mary Caffrey
The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com.jpg
September 25th 2023

Updates Are Driving the Field of MDS Forward, but Changes Still Needed

Laura Joszt, MA
In just the last 2 years there have been updates in classification, risk assessment, and response criteria in myelodysplastic syndromes (MDS), but additional efforts are needed to improve these, and there remains a need for better therapies.
1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo